Table 2

Cox regression analysis for cPFS and OS for entire cohort of patients with advanced melanoma

	cPFS univariable			cPFS multivariable			OS univariable			OS multivariable
	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Primary tumor type
Acral or mucosal vs cutaneous or unknown	1.57	1.09 to 2.26	0.016	1.85	1.23 to 2.79	0.003	1.84	1.23 to 2.76	0.003	2.13	1.36 to 3.34	0.001
Genomic subtype
BRAF or NRAS mt vs WT	1.28	0.94 to 1.77	0.120	1.40	0.99 to 1.96	0.056	1.16	0.81 to 1.65	0.423	1.46	1.00 to 2.13	0.052
Anti-PD1 regimen
PD1+CTLA4 vs PD1	0.63	0.45 to 0.90	0.011	0.57	0.38 to 0.86	0.007	0.60	0.40 to 0.90	0.014	0.42	0.28 to 0.65	<0.001
Line of therapy
First vs second or later	0.56	0.42 to 0.76	<0.001	0.72	0.51 to 1.01	0.062	0.53	0.38 to 0.75	<0.001		–
No of metastatic sites
>3 vs ≤3	2.15	1.56 to 2.98	<0.001	2.06	1.47 to 2.88	<0.001	2.23	1.56 to 3.18	<0.001	2.16	1.50 to 3.11	<0.001
M-stage
M1c/1d vs M0/1a/1b	1.45	1.06 to 2.00	0.022		–		1.79	1.24 to 2.57	0.002		–
LDH
≥1.5X ULN vs <1.5 x	1.83	1.32 to 2.54	<0.001	1.49	1.06 to 2.11	0.023	2.41	1.68 to 3.46	<0.001	1.88	1.28 to 2.76	<0.001
NLR
≥5 vs <5	1.39	0.98 to 1.96	0.062		–		1.72	1.19 to 2.51	0.004	1.59	1.06 to 2.36	0.023
Age
≥60 vs <60	0.83	0.61 to 1.11	0.215		–		1.21	0.86 to 1.71	0.267		–
Gender
Male vs female	0.78	0.58 to 1.06	0.114		–		0.82	0.58 to 1.15	0.254		–

cPFS, clinical progression-free survival; LDH, lactate dehydrogenase; NLR, neutrophil to lymphocyte ratio; OS, overall survival.